Skip to main content

Table 2 Results for measurement of the metabolite marker panel, APRI, FIB-4, and AST/ALT ratio in the prediction of liver fibrosis

From: Serum metabolite profiles are associated with the presence of advanced liver fibrosis in Chinese patients with chronic hepatitis B viral infection

 

Cohort 1 training set

Cohort 2 validation set

CLD vs. controls

Fibrosis vs. cirrhosis

S0–2 vs. S3-4

CLD vs. controls

Fibrosis vs. cirrhosis

S0–2 vs. S3-4

Metabolite marker panel

 AUROC (95% CI)#

0.997 (0.993–1)

0.941 (0.914–0.964)

0.918 (0.889–0.946)

0.977 (0.963–0.988)

0.844 (0.797–0.884)

0.807 (0.756–0.852)

 AUPR (95% CI)

0.994 (0.986–1)

0.87 (0.824–0.913)

0.892 (0.854–0.925)

0.993 (0.989–0.997)

0.827 (0.761–0.884)

0.817 (0.764–0.866)

 Cutoff value (sensitivity (%)/specificity (%)/F1 (%))†

0.434 (98.4/99/98.7)

0.01 (87/90.4/78.4)

− 0.115 (86.7/90.5/84.6)

0.434 (92.2/94.4/95.2)

0.01 (71.8/81.6/73.3)

− 0.115 (72.9/76.1/71.8)

FIB-4

 AUROC (95% CI)

0.848 (0.823–0.87)

0.869 (0.829–0.906)

0.802 (0.762–0.844)

0.707 (0.652–0.762)

0.758 (0.692–0.815)

0.739 (0.68–0.798)

 AUPR (95% CI)

0.863 (0.84–0.883)

0.725 (0.657–0.79)

0.707 (0.651–0.761)

0.897 (0.873–0.918)

0.726 (0.657–0.794)

0.726 (0.66–0.795)

 Cutoff value 1 (sensitivity (%)/specificity (%)/F1 (%))*

  

1.45 (68/73.6/62)

  

1.45 (81.5/42.5/68.1)

 Cutoff value 2 (sensitivity (%)/specificity (%)/F1 (%))*

  

3.25 (44.2/93.4/56.3)

  

3.25 (57/81.3/65.5)

APRI

 AUROC (95% CI)

0.973 (0.965–0.981)

0.698 (0.644–0.752)

0.647 (0.595–0.698)

0.879 (0.841–0.915)

0.608 (0.534–0.671)

0.595 (0.529–0.669)

 AUPR (95% CI)

0.977 (0.969–0.983)

0.416 (0.345–0.497)

0.492 (0.434–0.554)

0.958 (0.942–0.972)

0.53 (0.474–0.605)

0.542 (0.488–0.614)

 Cutoff value 1 (sensitivity (%)/specificity (%)/F1 (%))**

 

1 (33.9/86.2/37.1)

  

1 (22.7/84.4/32.4)

 

 Cutoff value 2 (sensitivity (%)/specificity (%)/F1 (%))**

 

2 (18.3/94.6/26.6)

  

2 (3.9/94.3/8.5)

 

AST/ALT

 AUROC (95% CI)

0.665 (0.631–0.697)

0.815 (0.766–0.862)

0.714 (0.668–0.759)

0.603 (0.54–0.657)

0.684 (0.619–0.75)

0.667 (0.597–0.728)

 AUPR (95% CI)

0.714 (0.685–0.747)

0.579 (0.496–0.674)

0.582 (0.516–0.654)

0.849 (0.819–0.875)

0.641 (0.573–0.721)

0.648 (0.583–0.727)

 Cutoff value 1 (sensitivity (%)/specificity (%)/F1 (%))***

  

0.8 (48.1/84.8/54.2)

  

0.8 (78.5/42.5/66.7)

 Cutoff value 2 (sensitivity (%)/specificity (%)/F1 (%))***

  

1 (33.1/92.8/45.1)

  

1 (65.9/59/63.8)

Comparison of AUROC

 Metabolite marker panel versus FIB-4****

p < 0.001

p < 0.001

p < 0.001

p < 0.001

p < 0.001

0.01

 Metabolite marker panel versus APRI****

p < 0.001

p < 0.001

p < 0.001

p < 0.001

p < 0.001

p < 0.001

 Metabolite marker panel versus AST/ALT****

p < 0.001

p < 0.001

p < 0.001

p < 0.001

p < 0.001

p < 0.001

  1. #95% CI was calculated using 1000 times bootstrap resampling on ROC and PR curves. CI confidence interval
  2. †Cutoff values were determined to maximize the sum of sensitivity and specificity for the cohort 1 training dataset
  3. *Predetermined cutoff values of FIB-4 were used (1.45 and 3.25 to distinguish extensive fibrosis)
  4. **Predetermined cutoff values of APRI were used (1.0 and 2.0 to distinguish cirrhosis)
  5. ***Predetermined cutoff values of AST/ALT were used (0.8 and 1.0 to distinguish extensive fibrosis)
  6. APRI AST-to-platelet ratio index, AST/ALT aspartate transaminase/alanine transaminase ratio, FIB-4 fibrosis-4 index, AUROC area under the receiver operating characteristic curve, AUPR area under the precision-recall (PR) curve
  7. ****Comparisons of AUROC between biomarker panel vs. FIB-4, AST/ALT, or APRI were performed using DeLong’s test
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us